EF Hutton Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Elemer Piros reiterates a Buy rating on ATAI Life Sciences (NASDAQ:ATAI) and maintains a $15 price target.
June 20, 2023 | 11:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Elemer Piros reiterates a Buy rating on ATAI Life Sciences and maintains a $15 price target.
The Buy rating and maintained price target by EF Hutton analyst Elemer Piros indicate a positive outlook for ATAI Life Sciences. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100